Fairvalue-Calculator Fairvalue-Calculator
EN DE

PharmGen Science, Inc (004720) Fair Value & Analysis

Healthcare · KR · Market cap 70.0B KRW

Price2,710 KRW
Fair Value4,630 KRW
Upside+70.8%
Quality95/100
Evidence: Medium Range 3,251 KRW – 5,791 KRW

Fair value as of: Jun 25, 2026

Analysis

PharmGen Science, Inc (004720) currently trades at 2,710 KRW, while our model-based Fair Value estimate is 4,630 KRW — implying the stock looks roughly 70.8% undervalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: medium) — always confirm before acting.

About the company

PharmGen Science, Inc. engages in the research and development, production, and sale of pharmaceutical products in South Korea. It provides prescription drugs, OTC drugs, diagnostic test kits, health and general foods, and cosmetics, as well as shampoo, conditioner, and hair oil products under the neomcell brand name. The company was formerly known as Wooridul Pharmaceutical Limited and changed its name to PharmGen Science, Inc. PharmGen Science, Inc. was founded in 1957 and is headquartered in Hwaseong-si, South Korea.

Open the full interactive analysis →

Similar stocks

Eli Lilly and Company (LLY) -64% Johnson & Johnson, (JNJ) -29% AbbVie Inc (ABBV) -42% Roche Holding (ROGN) -4% Merck & Co (MRCK34) -35% AstraZeneca PLC (A1ZN34) -31%

Frequently asked questions

Is PharmGen Science, Inc (004720) undervalued?
As of Jun 25, 2026, our model estimates a fair value of 4,630 KRW versus a price of 2,710 KRW — about +71% (undervalued). Model-based estimate, not financial advice.
What is the fair value of 004720?
Our 21-model fair value for PharmGen Science, Inc is 4,630 KRW (as of Jun 25, 2026), built from audited fundamentals. The current price is 2,710 KRW.
What is the quality score of 004720?
PharmGen Science, Inc has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.